The stock of Roivant Sciences Ltd (NASDAQ:ROIV) last traded at $11.50, down -1.63% from the previous session.
ROIV stock price is now -3.33% away from the 50-day moving average and 1.85% away from the 200-day moving average. The market capitalization of the company currently stands at $8.37B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Sukhatme Mayukh, Officer bought 412,584 shares of the company’s stock on Dec 18 ’24. The stock was bought for $4,969,631 at an average price of $12.05. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 20 ’24, President & COO Venker Eric sold 100,000 shares of the business’s stock. A total of $1,132,000 was realized by selling the stock at an average price of $11.32. This leaves the insider owning 606,525 shares of the company worth $6.98 million. A total of 48.44% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $9.69 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.43, and a quick ratio of 10.43. The fifty day moving average price for ROIV is $11.8966 and a two-hundred day moving average price translates $11.29165 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for 2024-09-30. The net profit margin was 3827.42% and return on equity was 159.08% for ROIV. The company reported revenue of $4.47 million for the quarter, compared to $3.65 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.67 percent.
